Literature DB >> 36225645

Biological heterogeneity of primary cancer-associated fibroblasts determines the breast cancer microenvironment.

Marika Musielak1,2,3, Oliwia Piwocka3,4, Katarzyna Kulcenty3, Karolina Ampuła3,4, Beata Adamczyk5, Igor Piotrowski1,3, Magdalena Fundowicz6, Marta Kruszyna-Mochalska1,7, Wiktoria M Suchorska1,3, Julian Malicki1,7.   

Abstract

Cancer-associated fibroblasts are a highly heterogeneous group of cells whose phenotypes and gene alterations are still under deep investigation. As a part of tumor microenvironment, they are the focus of a growing number of studies. Cancer-associated fibroblasts might become a new target of breast cancer therapy, but still more tests and analyses are needed to understand mechanisms and interactions between them and breast cancer cells. The study aimed to isolate cancer associated fibroblasts from breast cancer tissue and to phenotype the isolated cell lines. We focused on various cancer-associated fibroblast characteristic biomarkers and those that might differentiate various cancer-associated fibroblasts' subtypes. Patients with a histological diagnosis of invasive breast cancer (diameter ≤15 mm) and qualified for primary surgical treatment were enrolled in the study. Cell lines were isolated from breast cancer biopsy. For the phenotyping, we used flow cytometry, immunofluorescence and RT-qPCR analysis. Based on our study, there was no indication of a clear pattern in the cancer-associated fibroblasts' classification. Results of cancer-associated fibroblasts expression were highly heterogeneous, and specific subtypes were not defined. Moreover, comparing cancer-associated fibroblasts divided into groups based on BC subtypes from which they were isolated also did not allow to notice of any clear pattern of expressions. In the future, a higher number of analyzed cancer-associated fibroblast cell lines should be investigated to find expression schemes. AJCR
Copyright © 2022.

Entities:  

Keywords:  Cancer associated fibroblasts; breast cancer; oncology; primary cell lines; tumor microenvironment

Year:  2022        PMID: 36225645      PMCID: PMC9548006     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   5.942


  59 in total

1.  Subepithelial myofibroblasts are novel nonprofessional APCs in the human colonic mucosa.

Authors:  Jamal I Saada; Irina V Pinchuk; Carlos A Barrera; Patrick A Adegboyega; Giovanni Suarez; Randy C Mifflin; John F Di Mari; Victor E Reyes; Don W Powell
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

Review 2.  Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy.

Authors:  Patrick Micke; Arne Ostman
Journal:  Expert Opin Ther Targets       Date:  2005-12       Impact factor: 6.902

3.  Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen.

Authors:  Heather M Brechbuhl; Jessica Finlay-Schultz; Tomomi M Yamamoto; Austin E Gillen; Diana M Cittelly; Aik-Choon Tan; Sharon B Sams; Manoj M Pillai; Anthony D Elias; William A Robinson; Carol A Sartorius; Peter Kabos
Journal:  Clin Cancer Res       Date:  2016-10-04       Impact factor: 12.531

Review 4.  Biological subtypes of breast cancer: Prognostic and therapeutic implications.

Authors:  Ozlem Yersal; Sabri Barutca
Journal:  World J Clin Oncol       Date:  2014-08-10

5.  Comparison of immunocytochemistry, real-time quantitative RT-PCR and flow cytometry for detection of minimal residual disease in neuroblastoma.

Authors:  Marianne R S Ifversen; Bertil Kågedal; Lisa D Christensen; Catherine Rechnitzer; Bodil L Petersen; Carsten Heilmann
Journal:  Int J Oncol       Date:  2005-07       Impact factor: 5.650

Review 6.  Fibroblasts-a diverse population at the center of it all.

Authors:  J Michael Sorrell; Arnold I Caplan
Journal:  Int Rev Cell Mol Biol       Date:  2009       Impact factor: 6.813

7.  CD44+ fibroblasts increases breast cancer cell survival and drug resistance via IGF2BP3-CD44-IGF2 signalling.

Authors:  Yonglei Liu; Conghui Yu; Yonggang Wu; Xiangjun Sun; Quanping Su; Cuiping You; Hongwu Xin
Journal:  J Cell Mol Med       Date:  2017-05-18       Impact factor: 5.310

8.  CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors.

Authors:  Masayuki Ishibashi; Shinya Neri; Hiroko Hashimoto; Tomoyuki Miyashita; Tatsuya Yoshida; Yuka Nakamura; Hibiki Udagawa; Keisuke Kirita; Shingo Matsumoto; Shigeki Umemura; Kiyotaka Yoh; Seiji Niho; Masahiro Tsuboi; Kenkichi Masutomi; Koichi Goto; Atsushi Ochiai; Genichiro Ishii
Journal:  Sci Rep       Date:  2017-04-21       Impact factor: 4.379

9.  Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21.

Authors:  Ali Hussain; Veronique Voisin; Stephanie Poon; Christina Karamboulas; Ngoc Hoang Bao Bui; Jalna Meens; Julia Dmytryshyn; Victor W Ho; Kwan Ho Tang; Joshua Paterson; Blaise A Clarke; Marcus Q Bernardini; Gary D Bader; Benjamin G Neel; Laurie E Ailles
Journal:  J Exp Med       Date:  2020-08-03       Impact factor: 14.307

Review 10.  Stromal Fibroblast in Age-Related Cancer: Role in Tumorigenesis and Potential as Novel Therapeutic Target.

Authors:  Abdelouahid Elkhattouti; Mohamed Hassan; Christian R Gomez
Journal:  Front Oncol       Date:  2015-07-27       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.